- Home
- EPRT vs MDGL Comparison
EPRT vs MDGL Comparison
Compare EPRT & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EPRT | MDGL |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 12.5B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | EPRT | MDGL |
|---|---|---|
| Price | $30.54 | $570.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $35.50 | ★ $553.08 |
| AVG Volume (30 Days) | ★ 1.8M | 313.6K |
| Earning Date | 10-22-2025 | 11-04-2025 |
| Dividend Yield | ★ 4.06% | N/A |
| EPS Growth | ★ 8.17 | N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | $531,061,000.00 | ★ $740,640,000.00 |
| Revenue This Year | $23.59 | $436.04 |
| Revenue Next Year | $17.43 | $53.17 |
| P/E Ratio | $24.56 | ★ N/A |
| Revenue Growth | 23.93 | ★ 864.21 |
| 52 Week Low | $27.44 | $265.00 |
| 52 Week High | $33.35 | $605.00 |
Technical Indicators
Market Signals| Indicator | EPRT | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 59.89 |
| Support Level | $30.37 | $546.20 |
| Resistance Level | $31.47 | $589.67 |
| Average True Range (ATR) | 0.52 | 22.68 |
| MACD | -0.12 | -6.14 |
| Stochastic Oscillator | 4.42 | 45.10 |
Price Performance
Historical ComparisonAbout EPRT Essential Properties Realty Trust Inc.
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.